Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Buy
58
IDXX Quote, Financials, Valuation and Earnings
Last price:
$433.86
Seasonality move
:
8.6%
Day range:
$427.70 - $440.26
52-week range:
$356.14 - $548.88
Dividend yield:
0%
P/E ratio:
41.00x
P/S ratio:
9.34x
P/B ratio:
22.30x
Volume:
935.9K
Avg. volume:
946K
1-year change:
-13.08%
Market cap:
$35.6B
Revenue:
$3.9B
EPS (TTM):
$10.67
Analysts' Opinion
-
Consensus RatingIDEXX Laboratories has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $486.13, IDEXX Laboratories has an estimated upside of 11.13% from its current price of $433.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $385.00 representing 11.99% downside risk from its current price of $433.99.
Fair Value
-
According to the consensus of 9 analysts, IDEXX Laboratories has 11.13% upside to fair value with a price target of $486.13 per share.
IDXX vs. S&P 500
-
Over the past 5 trading days, IDEXX Laboratories has overperformed the S&P 500 by 1.64% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
IDEXX Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IDEXX Laboratories has grown year-over-year revenues for 40 quarters straight. In the most recent quarter IDEXX Laboratories reported revenues of $954.3M.
Earnings Growth
-
IDEXX Laboratories has grown year-over-year earnings for 2 quarters straight. In the most recent quarter IDEXX Laboratories reported earnings per share of $2.62.
Enterprise value:
36.2B
EV / Invested capital:
--
Price / LTM sales:
9.34x
EV / EBIT:
31.69x
EV / Revenue:
9.28x
PEG ratio (5yr expected):
6.88x
EV / Free cash flow:
45.30x
Price / Operating cash flow:
45.62x
Enterprise value / EBITDA:
28.45x
Gross Profit (TTM):
$2.4B
Return On Assets:
26.63%
Net Income Margin (TTM):
22.78%
Return On Equity:
56.57%
Return On Invested Capital:
35.72%
Operating Margin:
27.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $3.4B | $3.7B | $3.9B | $901.6M | $954.3M | |
| Gross Profit | $2B | $2.2B | $2.4B | $526.2M | $570.7M | |
| Operating Income | $898.8M | $1.1B | $1.1B | $245.3M | $261.7M | |
| EBITDA | $1B | $1.2B | $1.3B | $278.7M | $297.6M | |
| Diluted EPS | $8.03 | $10.07 | $10.67 | $2.32 | $2.62 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $955.7M | $1.1B | $1.5B | $1.4B | |
| Total Assets | $2.3B | $2.4B | $2.7B | $3.3B | $3.3B | |
| Current Liabilities | $582.8M | $763.6M | $1.2B | $951.5M | $1.1B | |
| Total Liabilities | $1.7B | $1.7B | $2.1B | $1.8B | $1.7B | |
| Total Equity | $632.8M | $690M | $608.7M | $1.5B | $1.6B | |
| Total Debt | $908.5M | $923.7M | $1.3B | $947.9M | $867.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $543M | $906.5M | $929M | $249.9M | $262M | |
| Cash From Investing | -$195.4M | -$125.3M | -$207.1M | -$30.4M | -$39.8M | |
| Cash From Financing | -$370.9M | -$442M | -$878.1M | -$101.8M | -$232.8M | |
| Free Cash Flow | $384.1M | $772.9M | $798.1M | $217.3M | $222.8M | |
IDXX
Sector
Market Cap
$35.6B
$35M
Price % of 52-Week High
79.7%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
2.57%
-0.9%
1-Year Price Total Return
-10.59%
-38.53%
Beta (5-Year)
1.496
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$422.63
200-day SMA
Sell
Level
$448.44
Bollinger Bands (100)
Buy
Level
407.35 - 446.29
Chaikin Money Flow
Buy
Level
131.5M
20-day SMA
Buy
Level
$408.44
Relative Strength Index (RSI14)
Buy
Level
57.94
ADX Line
Buy
Level
23.07
Williams %R
Sell
Level
-5.1674
50-day SMA
Buy
Level
$423.41
MACD (12, 26)
Buy
Level
3.58
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
138.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.6352)
Buy
CA Score
(Annual)
Level (1.4341)
Buy
Beneish M-Score
(Annual)
Level (-2.4769)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.8175)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Stock Forecast FAQ
In the current month, IDXX has received 3 Buy ratings 6 Hold ratings, and 0 Sell ratings. The IDXX average analyst price target in the past 3 months is $486.13.
-
Where Will IDEXX Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that IDEXX Laboratories share price will rise to $486.13 per share over the next 12 months.
-
What Do Analysts Say About IDEXX Laboratories?
Analysts are divided on their view about IDEXX Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IDEXX Laboratories is a Sell and believe this share price will drop from its current level to $385.00.
-
What Is IDEXX Laboratories's Price Target?
The price target for IDEXX Laboratories over the next 1-year time period is forecast to be $486.13 according to 9 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is IDXX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IDEXX Laboratories is a Hold. 6 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IDXX?
You can purchase shares of IDEXX Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IDEXX Laboratories shares.
-
What Is The IDEXX Laboratories Share Price Today?
IDEXX Laboratories was last trading at $433.86 per share. This represents the most recent stock quote for IDEXX Laboratories. Yesterday, IDEXX Laboratories closed at $433.99 per share.
-
How To Buy IDEXX Laboratories Stock Online?
In order to purchase IDEXX Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 28
Saia [SAIA] is down 3.49% over the past day.
Sell
36
APPF alert for Apr 29
AppFolio [APPF] is up 5.02% over the past day.
Sell
15
KNSL alert for Apr 29
Kinsale Capital Group [KNSL] is up 0.99% over the past day.
